此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

2026年6月19日 更新者:Xiaomu Li、First Affiliated Hospital of Zhejiang University

Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (<300 vs >=300 mg/g), to oral finerenone (10 or 20 mg once daily, titrated by serum potassium and eGFR) or matching placebo, on top of standard background therapy, for 180 days, followed by a 30-day off-treatment follow-up. Albuminuria regression is defined as both an improvement in Kidney Disease: Improving Global Outcomes albuminuria category, from A3 to A2 or A1, or from A2 to A1, and a more than 30% reduction in urinary albumin-to-creatinine ratio from baseline. The outcome will be reported as the percentage of participants meeting this definition at Day 180.

研究概览

详细说明

Background and rationale: Finerenone is an oral, highly selective nonsteroidal mineralocorticoid receptor antagonist approved in China for the treatment of chronic kidney disease associated with type 2 diabetes (with albuminuria). In the phase III FIDELIO-DKD and FIGARO-DKD trials, finerenone added to a maximum tolerated dose of a renin-angiotensin system inhibitor significantly and durably reduced the urine albumin-to-creatinine ratio (UACR) and lowered the risk of kidney and cardiovascular events, with a manageable hyperkalemia risk. A meaningful reduction in albuminuria is an established early surrogate for slowing CKD progression and reducing cardiovascular risk. This study evaluates whether finerenone can achieve early regression of albuminuria in patients with type 2 diabetes and CKD.

Design: This is a multicenter, randomized, double-blind, placebo-controlled trial conducted at up to 12 sites in China. A planned 148 participants are allocated 1:1 to finerenone or matching placebo using central, block randomization (interactive response technology), stratified by baseline UACR (<300 vs >=300 mg/g). Participants and investigators are blinded; placebo tablets are identical in appearance to finerenone, and intervention-period UACR samples are assayed centrally after study completion to preserve blinding.

Population: Eligible participants are adults with type 2 diabetes and CKD (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who have received a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days and have serum potassium <= 5.0 mmol/L.

Intervention and dose titration: The starting dose is determined by screening eGFR: 10 mg once daily for 30 <= eGFR < 60 mL/min/1.73 m^2, or 20 mg once daily for eGFR >= 60 mL/min/1.73 m^2. The dose is up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR at scheduled and, if needed, unscheduled safety visits. Treatment continues for 180 days.

Visit schedule: a screening period (Day -30 to -1; V1); a treatment period ; and an off-treatment follow-up at Day 210 +/- 5 (V7). Unscheduled safety visits and early-discontinuation visits are performed as needed.

Endpoints: The primary endpoint is the albuminuria regression rate at 180 days, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline. Secondary endpoints include the change in UACR, the rate of regression to normoalbuminuria, the proportions achieving >=30/40/50% UACR reduction, KDIGO GFR-Albuminuria category improvement, the change in UACR 30 days after discontinuation, the change in eGFR slope, and the change in blood pressure. Safety endpoints include adverse events, serious adverse events, and adverse events of special interest (notably serum potassium changes and hyperkalemia). Exploratory endpoints also included.

研究类型

介入性

注册 (估计的)

148

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国
        • The First Affiliated Hospital of Chongqing Medical University
        • 接触:
          • Zhihong Wang
          • 电话号码:+8613883021919
    • Fujian
      • Fuzhou、Fujian、中国
        • Fujian Provincial Hospital
        • 接触:
          • Junping Wen
          • 电话号码:+8613559925729
    • Guangdong
      • Foshan、Guangdong、中国
        • Sanshui Hospital, Zhujiang Hospital, Southern Medical University
        • 接触:
          • Zhen Zhang
          • 电话号码:+8615913162742
      • Guangzhou、Guangdong、中国
        • Nanfang Hospital, Southern Medical University
        • 接触:
          • Junyu Xue
          • 电话号码:+8618613166333
    • Jiangsu
      • Nantong、Jiangsu、中国
        • Nantong First People's Hospital
        • 接触:
          • Xueqin Wang
          • 电话号码:+8613813609566
      • Suqian、Jiangsu、中国
        • The First People's Hospital of Suqian
        • 接触:
          • Hong Zhu
          • 电话号码:+8618012186759
      • Suzhou、Jiangsu、中国
        • Suzhou Science and Technology City Hospital
        • 接触:
          • Zhimin Ma
          • 电话号码:+8617715187073
    • Shaanxi
      • Xi'an、Shaanxi、中国
        • Xi'an Daxing Hospital
        • 接触:
          • Ying Xing
          • 电话号码:+8613991955717
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国
        • Zhongshan hospital, Fudan university
        • 接触:
          • Yuejuan Liu
          • 电话号码:+8613472844268
      • Shanghai、Shanghai Municipality、中国
        • Shanghai Municipal Hospital of Traditional Chinese Medicine
        • 接触:
          • Feng Tao
          • 电话号码:+8613818808324
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • 接触:
      • Ningbo、Zhejiang、中国
        • The First Affiliated Hospital of Ningbo University
        • 接触:
          • Li Li
          • 电话号码:+8613757426626
      • Wenzhou、Zhejiang、中国
        • The First Affiliated Hospital of Wenzhou Medical University
        • 接触:
          • Hong Zhu
          • 电话号码:+8613758712421

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • 1. Age >= 18 years at the time of signing informed consent, male or female.
  • 2. Type 2 diabetes mellitus.
  • 3. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) >= 30 mL/min/1.73 m^2, and UACR 30-2000 mg/g (mean of 3 measurements).
  • 4. Serum potassium <= 5.0 mmol/L.
  • 5. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.
  • 6. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.

Exclusion Criteria:

  • 1. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.
  • 2. HbA1c >= 8.0%.
  • 3. On renal replacement therapy.
  • 4. Acute kidney injury within 180 days before the screening visit.
  • 5. Hepatic impairment (Child-Pugh class C).
  • 6. Blood pressure > 160/100 mmHg, or systolic blood pressure < 90 mmHg, at the screening visit.
  • 7. Bilateral renal artery stenosis.
  • 8. Known hypersensitivity to the study drug (active substance or excipients).
  • 9. Treatment with finerenone within 60 days before screening.
  • 10. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.
  • 11. NYHA class II-IV heart failure.
  • 12. Addison's disease.
  • 13. Gastrointestinal surgery that may affect drug absorption.
  • 14. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy < 12 months).
  • 15. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.
  • 16. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.
  • 17. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).
  • 18. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.
  • 19. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.
  • 20. History of alcohol or drug abuse.
  • 21. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.
  • 22. Any other condition deemed by the investigator to make the participant unsuitable for the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Finerenone
Finerenone film-coated tablets, orally once daily, on top of standard background therapy. Starting dose determined by screening eGFR: 10 mg if 30 <= eGFR < 60 mL/min/1.73 m^2, or 20 mg if eGFR >= 60 mL/min/1.73 m^2. Dose up-titrated to 20 mg, maintained, interrupted, or down-titrated to 10 mg based on serum potassium and eGFR. Treatment duration 180 days.
Oral finerenone 10 mg or 20 mg once daily, with dose titration by serum potassium and eGFR, for 180 days.
安慰剂比较:Placebo
Matching placebo tablets identical in appearance to finerenone, orally once daily, on top of standard background therapy, following the same dosing and titration schedule. Treatment duration 180 days.
Matching placebo tablets, identical in appearance to finerenone, orally once daily, following the same dosing and titration schedule, for 180 days.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Albuminuria regression rate
大体时间:180 days
Proportion of participants achieving albuminuria regression, defined as a reduction in UACR KDIGO albuminuria category (A3 to A2 or A1, or A2 to A1) together with a >=30% reduction in UACR from baseline.
180 days

次要结果测量

结果测量
措施说明
大体时间
Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio
大体时间:Baseline and 180 days
Urinary albumin-to-creatinine ratio will be measured in mg/g. Percent change from baseline will be calculated as: (Day 180 UACR - baseline UACR) / baseline UACR × 100%.
Baseline and 180 days
Percentage of Participants With Normoalbuminuria
大体时间:180 days
Normoalbuminuria is defined as urinary albumin-to-creatinine ratio less than 30 mg/g at Day 180.
180 days
Percentage of Participants by UACR Reduction Response Category at Day 180
大体时间:Baseline to Day 180
Percent reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to Day 180 will be calculated for each participant. Participants will be classified into one of four mutually exclusive UACR reduction response categories: no more than 30% reduction, more than 30% to no more than 40% reduction, more than 40% to no more than 50% reduction, and more than 50% reduction. Participants with no reduction or an increase in UACR will be included in the no more than 30% reduction category. The outcome will be reported as the percentage of participants in each response category.
Baseline to Day 180
Percentage of Participants With Improvement in Kidney Disease: Improving Global Outcomes Albuminuria Category at Day 180
大体时间:Baseline to Day 180
Improvement in albuminuria category is defined as a change from A3 to A2 or A1, or from A2 to A1, according to Kidney Disease: Improving Global Outcomes urinary albumin-to-creatinine ratio categories.
Baseline to Day 180
Change From Day 180 to Day 210 in Urinary Albumin-to-Creatinine Ratio
大体时间:Day 180 to Day 210
Change in urinary albumin-to-creatinine ratio from Day 180 to Day 210 will be assessed in mg/g, corresponding to the 30-day off-treatment follow-up period.
Day 180 to Day 210
Estimated Glomerular Filtration Rate Slope Through Day 180
大体时间:Baseline through Day 180
Estimated glomerular filtration rate will be calculated using the CKD-EPI equation. The eGFR slope through Day 180 will be estimated from serial eGFR measurements and reported in mL/min/1.73 m2 per year.
Baseline through Day 180
Change From Baseline in Systolic Blood Pressure at Day 180
大体时间:Baseline to Day 180
Change in systolic blood pressure from baseline to Day 180 will be assessed in mmHg.
Baseline to Day 180
Change From Baseline in Diastolic Blood Pressure at Day 180
大体时间:Baseline to Day 180
Change in diastolic blood pressure from baseline to Day 180 will be assessed in mmHg.
Baseline to Day 180

其他结果措施

结果测量
措施说明
大体时间
Percentage of Participants With Adverse Events
大体时间:From first dose through Day 210
The outcome will be reported as the percentage of participants experiencing at least one adverse event from first dose through the end of the 30-day off-treatment follow-up period.
From first dose through Day 210
Percentage of Participants With Serious Adverse Events
大体时间:From first dose through Day 210
The outcome will be reported as the percentage of participants experiencing at least one serious adverse event from first dose through the end of the 30-day off-treatment follow-up period.
From first dose through Day 210
Adverse events of special interest (AESI)
大体时间:Up to 210 days
Including change in serum potassium and incidence of hyperkalemia, incidence of eGFR decline >30% at Day 30, reversibility of eGFR after discontinuation, acute kidney injury, urogenital infection, severe hypoglycemia, symptomatic hypotension, and ketoacidosis
Up to 210 days
Change in Composite MRI-PDFF-derived Peri-organ Visceral Fat Fraction
大体时间:Baseline and 180 days
Abdominal magnetic resonance imaging proton density fat fraction will be used to quantify visceral fat fraction (%) in prespecified perirenal, peripancreatic, and perihepatic regions of interest. A composite peri-organ visceral fat fraction will be calculated for each participant as the arithmetic mean of the region-specific MRI-PDFF values from the perirenal, peripancreatic, and perihepatic regions. The outcome will be reported as the percentage-point change in the composite peri-organ visceral fat fraction from baseline to Day 180.
Baseline and 180 days
Change in Urine Metabolomic Composite Score
大体时间:Baseline to Day 180
Urine metabolomic features will be measured using a prespecified metabolomics platform. Normalized metabolite feature intensities will be standardized, and a urine metabolomic composite score will be calculated according to the statistical analysis plan. The outcome will be reported as change in composite score from baseline to Day 180.
Baseline to Day 180

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2027年10月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年6月14日

首先提交符合 QC 标准的

2026年6月19日

首次发布 (实际的)

2026年6月25日

研究记录更新

最后更新发布 (实际的)

2026年6月25日

上次提交的符合 QC 标准的更新

2026年6月19日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared publicly.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅